Evidence map›Paper›PMID 39249507›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites.

Abbas Agaimy, Morgan Blakely, Gerben E Breimer, Annett Hölsken, Sjors A Koppes, Norbert Meidenbauer, Johannes A Rijken, Arno Schad, Adrian G Simon, Robert Stoehr and 2 more

Abstract readComparative Study
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Immunohistochemical evaluation of CREM in CREB-rearranged mesenchymal tumors and their mimics.Virchows Archiv : an international journal of pathology · 2025
    Article
  5. [Challenges in the research and diagnosis of rare diseases].Pathologie (Heidelberg, Germany) · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abbas AgaimyInstitute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany. abbas.agaimy@uk-erlangen.de.
Morgan BlakelyDepartment of Pathology, Kaiser Santa Clara, Santa Clara, CA, 95051, USA.
Gerben E BreimerDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Annett HölskenInstitute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany.
Sjors A KoppesDepartment of Pathology, Erasmus University Medical Centre, Rotterdam, Netherlands.
Norbert MeidenbauerDepartment of Internal Medicine 5-Hematology and Oncology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Johannes A RijkenDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Arno SchadDepartment of Pathology, University of Mainz, Mainz, Germany.
Adrian G SimonDepartment of Pathology, University Hospital of Cologne, University of Cologne, Cologne, Germany.
Robert StoehrInstitute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany.
Justin A BishopDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Nasir Ud DinDepartment of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the wide use of RNA sequencing technologies, the family of FET::CREB fusion mesenchymal neoplasms has expanded rapidly to include potentially aggressive neoplasms, not fitting any well established WHO entity. Recently, a group of intra-abdominal FET(EWSR1/FUS)::CREB(CREM/ATF1) fused unclassified neoplasms has been reported followed by recent recognition of an analogous extra-abdominal category of unclassified neoplasms carrying EWSR1::ATF1 fusions. We describe 9 additional tumors (5 extra-abdominal and 4 abdominal) carrying an EWSR1::CREM (n = 8) and FUS::CREM (n = 1) fusion. Patients were 7 females and 2 males aged 10 to 75 years (median, 34). Extra-abdominal tumors originated in the head and neck (2 sinonasal, 1 orbital) and soft tissues (1 gluteal, 1 inguinal). Abdominal tumors involved stomach (2), mesentery (1), and kidney (1). Tumor size ranged from 3.5 to 11 cm (median, 6). Treatment was radical surgery with (5) or without (2) neo/adjuvant radio/chemotherapy. Extended follow-up of 5 patients (21-52 months; median, 24) showed an aggressive course in two (40%); one died of disseminated metastases 52 months after several intensified chemotherapy regimens, and one was alive with progressive abdominal disease at 21 months. The immunophenotype of the two subcohorts was significantly overlapping with variable expression of EMA (7 of 8), keratin AE1/AE3 (5 of 9), CD99 (4 of 7), MUC4 (2 of 8), ALK (3 of 8), synaptophysin (3 of 9), chromogranin (1 of 8), CD34 (3 of 6), CD30 (1 of 6), PAX8 (1 of 7), and inhibin (1 of 7), but no reactivity with desmin (0 of 8), S100 (0 of 8), and SOX10 (0 of 8). This series further solidifies the notion that FET::CREB fusions are not limited to the triad of angiomatoid fibrous histiocytoma, clear cell sarcoma, and malignant gastrointestinal neuroectodermal tumor, but characterize an emerging family of potentially aggressive neoplasms occurring at both intra- and extra-abdominal sites. These tumors underscore the promiscuity of the FET::CREB fusions and highlight the pivotal role of phenotype-oriented classification of these neoplasms that share the same genotype, still featuring significant biological and behavioral distinctness.

Indexed as

Abdominal NeoplasmsCyclic AMP Response Element ModulatorOncogene Proteins, FusionAdolescentAdultAgedBiomarkers, TumorChildFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedRNA-Binding Protein EWSRNA-Binding Protein FUSSarcomaBiomarkers, TumorCREM protein, humanCyclic AMP Response Element ModulatorEWSR1 protein, humanOncogene Proteins, FusionRNA-Binding Protein EWSRNA-Binding Protein FUSConstitutional symptomsEwing sarcomaGenetic landscapeNext generation sequencingPrecision medicineProfiling

Identifiers

PMID39249507
PMCPMC11666796

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.